2. Vaxcyte Inc. (NASDAQ:PCVX)
Stock Upside: 123.85%
Market Capitalization: $7.09 billion
Vaxcyte, Inc. (NASDAQ) ranks second among the most promising healthcare stocks according to Wall Street analysts, and Vaxcyte, Inc. (NASDAQ) brings a vaccine-development story with unusually large global health implications. Trading at $51.44, with Vaxcyte, Inc. (NASDAQ) up 1.52%, the company has a market capitalization of $7.09 billion and a stock upside of 123.85%. For investors searching for vaccine stocks, clinical-stage biotech stocks, infectious disease stocks, healthcare stocks with high upside, and Wall Street analyst healthcare picks, Vaxcyte, Inc. (NASDAQ) stands out because it is working on a disease area where no approved vaccine currently exists.
Vaxcyte, Inc. (NASDAQ) announced on June 2 that it had dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1. Vaxcyte, Inc. (NASDAQ) is developing VAX-A1 as an experimental vaccine against Group A Streptococcus, also known as Group A Strep. For Vaxcyte, Inc. (NASDAQ), this first dosing marks an important transition from preclinical development into human testing. In biotech and vaccine development, first-in-human studies are major milestones because they begin to answer the basic questions of safety, tolerability, dosing, and immune response.
Vaxcyte, Inc. (NASDAQ) is entering a potentially significant global disease area. Vaxcyte, Inc. (NASDAQ) estimates that Group A Strep is responsible for around 800 million illnesses globally every year, with conditions ranging from common strep throat to severe, life-threatening infections and long-term complications such as rheumatic heart disease. Despite that disease burden, Vaxcyte, Inc. (NASDAQ) noted that no approved Group A Strep vaccine exists anywhere in the world. For investors following Vaxcyte, Inc. (NASDAQ), that is the core of the opportunity: a massive infectious disease burden with no approved vaccine solution.
Vaxcyte, Inc. (NASDAQ) plans to enroll 80 healthy adults aged 18 to 40 in Australia for the Phase 1 trial. Vaxcyte, Inc. (NASDAQ) said Australia was chosen because the country has high rates of Group A Strep disease and established research networks with strong expertise in studying it. For Vaxcyte, Inc. (NASDAQ), trial location is not just a logistical detail because vaccine studies benefit from regions where researchers understand the disease burden, patient population, and clinical monitoring needs.
Vaxcyte, Inc. (NASDAQ) will structure the trial in two stages. Stage 1 will include 12 participants who will serve as a safety checkpoint before an independent safety board reviews the results and decides whether Vaxcyte, Inc. (NASDAQ) can expand into Stage 2. All participants will receive two doses of VAX-A1 or placebo, spaced around two months apart, and Vaxcyte, Inc. (NASDAQ) will monitor them for six months after the final dose. The trial will also test low, mid, and high dose levels so Vaxcyte, Inc. (NASDAQ) can find the best balance between immune response and tolerability.
Vaxcyte, Inc. (NASDAQ) is a clinical-stage biotechnology company, and its vaccine work gives Vaxcyte, Inc. (NASDAQ) one of the more direct public-health stories on this list. With a $7.09 billion market capitalization, 57 hedge fund holders, and a 123.85% stock upside estimate, Vaxcyte, Inc. (NASDAQ) ranks near the top because Wall Street analysts see significant potential. For investors looking for vaccine stocks to watch, infectious disease biotech stocks, and healthcare stocks with major upside potential, Vaxcyte, Inc. (NASDAQ) has a clear thesis: a first-in-human vaccine candidate targeting a disease that affects hundreds of millions of people worldwide.
Click next to see the following stock...
